Paperpal Prime Logo

Therapeutic Advances in Endocrinology and Metabolism : Impact Factor & More

eISSN: 2042-0196pISSN: 2042-0188
JournalOpen Access

Key Metrics

CiteScore
5.3
Impact Factor
< 5
SJR
Q3Endocrinology, Diabetes and Metabolism
SNIP
1.33
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Therapeutic Advances in Endocrinology and Metabolism

Therapeutic Advances in Endocrinology and Metabolism Journal Specifications

Overview
Publisher SAGE PUBLICATIONS LTD
Language English
Frequency Continuous publication
Article Processing ChargesUSD 2300
Publication Time8
Editorial Review ProcessAnonymous peer review
General Details
LanguageEnglish
FrequencyContinuous publication
Publication Start Year2010
Publisher URLVisit website
Website URLVisit website
Publication Details
PlagiarismVisit website
Publication Time 8
Waiver PolicyVisit website
Editorial Review Detail
Editorial TeamVisit website
Review ProcessAnonymous peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Copyright DetailsVisit website
Deposit PolicySherpa/Romeo
License typeCC BY, CC BY-NC
OA statementVisit website
View less

Planning to publish in Therapeutic Advances in Endocrinology and Metabolism ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Therapeutic Advances in Endocrinology and Metabolism

Beyond glycemic control: clinical cardiovascular effects of tirzepatide\u2014a narrative review
  • 28 Jul 2026
  • Therapeutic Advances in Endocrinology and Metabolism
GLP-1 receptor agonists in primary care: readiness, equity, and the risk of a two-tiered obesity treatment landscape
  • 27 Jul 2026
  • Therapeutic Advances in Endocrinology and Metabolism
Automated insulin delivery use in a woman living with type 1 diabetes on peritoneal dialysis: a case report
  • 16 Jul 2026
  • Therapeutic Advances in Endocrinology and Metabolism
Determination of the relationship between raftlin, oxidative stress levels, and vitamin D receptor gene polymorphism in diabetic patients
  • 15 Jul 2026
  • Therapeutic Advances in Endocrinology and Metabolism
Diabetes-type-specific thyroid safety of GLP-1 receptor agonists: evidence from a large real-world cohort
  • 30 Jun 2026
  • Therapeutic Advances in Endocrinology and Metabolism
Association of prediabetes phenotypes with metabolic dysfunction-associated fatty liver disease and liver fibrosis: a population-based study
  • 11 Jun 2026
  • Therapeutic Advances in Endocrinology and Metabolism
Beyond glycemic control: clinical cardiovascular effects of tirzepatide\u2014a narrative review
  • 28 Jul 2026
  • Therapeutic Advances in Endocrinology and Metabolism
GLP-1 receptor agonists in primary care: readiness, equity, and the risk of a two-tiered obesity treatment landscape
  • 27 Jul 2026
  • Therapeutic Advances in Endocrinology and Metabolism
Automated insulin delivery use in a woman living with type 1 diabetes on peritoneal dialysis: a case report
  • 16 Jul 2026
  • Therapeutic Advances in Endocrinology and Metabolism
Determination of the relationship between raftlin, oxidative stress levels, and vitamin D receptor gene polymorphism in diabetic patients
  • 15 Jul 2026
  • Therapeutic Advances in Endocrinology and Metabolism
Diabetes-type-specific thyroid safety of GLP-1 receptor agonists: evidence from a large real-world cohort
  • 30 Jun 2026
  • Therapeutic Advances in Endocrinology and Metabolism
Association of prediabetes phenotypes with metabolic dysfunction-associated fatty liver disease and liver fibrosis: a population-based study
  • 11 Jun 2026
  • Therapeutic Advances in Endocrinology and Metabolism

FAQs on Therapeutic Advances in Endocrinology and Metabolism